Brinsupri access in Kuwait: the DRD-MOH named-patient pathway
How patients in the State of Kuwait legally obtain Brinsupri (brensocatib) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Quick orientation
Patients in Kuwait access Brinsupri (brensocatib) for non-cystic-fibrosis bronchiectasis in adults to reduce the frequency of pulmonary exacerbations through the DRD-MOH named-patient pathway, a the Drug and Food Control Administration of the Kuwait Ministry of Health-administered mechanism that allows a Kuwaiti-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in KWD.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Reserved for you.
Why Kuwaiti patients need Brinsupri through the named-patient pathway
The State of Kuwait operates a structured pharmaceutical regulatory environment. Brinsupri (brensocatib) is regulated through DRD-MOH (the Drug and Food Control Administration of the Kuwait Ministry of Health) channels, and a Kuwaiti family asking for Brinsupri is rarely asking for a medicine that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to.
Four converging patterns drive these cases. First, indication lag. Brinsupri's newer FDA-approved indications and dosing expansions often reach local registration 12 to 36 months after the US label. A family whose treating physician has documented a clear FDA-label fit may still find that the local label has not caught up. Second, presentation gaps. The exact strength, weight-banded dose, or pen format the prescriber needs may not be stocked at the local agent even when the medicine is registered. Third, payer denial. MOH public coverage, GIG Kuwait, and Warba Insurance each assess specialty therapies case by case, and step-therapy or formulary rules often produce denials even when the drug is on the local register. Cash-pay families pursue cross-border supply rather than wait through appeals. Fourth, continuity of supply. When a US-stable patient relocates to Kuwait or visits family for an extended period, maintaining the original FDA-sourced regimen matters more than switching to a different local presentation.
In each pattern, the DRD-MOH named-patient pathway is the mechanism that connects a Kuwaiti-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient. Clinically, Brinsupri is a first-in-class reversible inhibitor of dipeptidyl peptidase 1 (DPP1, also known as cathepsin C), the enzyme that activates neutrophil serine proteases (neutrophil elastase, proteinase 3, cathepsin G); inhibition reduces airway neutrophilic inflammation that drives bronchiectasis exacerbations, and the named-patient route preserves that mechanism rather than substituting a non-equivalent local option.
Current regulatory status of Brinsupri in Kuwait
Brinsupri (brensocatib; Insmed) is a first-in-class oral reversible inhibitor of dipeptidyl peptidase 1 (DPP1, cathepsin C), the enzyme that activates neutrophil serine proteases. The drug received FDA approval in 2025 for adults with non-cystic-fibrosis bronchiectasis to reduce the frequency of pulmonary exacerbations. The dosing is 25 mg once daily.
As of 2026-05-31, no public Kuwait MOH KDFC registration record for brensocatib has been observed; the drug is too recent for a routine Kuwait registration timeline. Access proceeds through the KDFC personal-import / named-patient route under Pharmacy Practice Law No. 28 of 1996 and Ministerial Decree 302/2002.
The non-cystic-fibrosis bronchiectasis indication requires diagnostic confirmation by high-resolution CT thorax showing bronchiectatic changes, exclusion of cystic fibrosis (sweat chloride testing and / or CFTR genetic testing where clinically appropriate), and documentation of exacerbation frequency in the prior 12 to 24 months. The file specifies the diagnostic confirmation, the exacerbation history (typically two or more pulmonary exacerbations in the prior year for the FDA-labelled phenotype), and the prior therapy history (inhaled antibiotic chronic suppression, macrolide chronic suppression, airway-clearance physiotherapy).
Last verified by ARCH-74: 2026-05-31.
Named tertiary centres in Kuwait where Brinsupri is dispensed
Brensocatib for non-cystic-fibrosis bronchiectasis is a respiratory medicine product. Kuwaiti tertiary centres with adult pulmonology services:
- Al-Sabah Hospital, Shuwaikh - Department of Pulmonology / Chest Medicine; large-volume MOH tertiary respiratory service.
- Sheikh Jaber Al-Ahmad Al-Sabah Hospital, Kuwait City - Department of Pulmonology; multi-specialty MOH tertiary.
- Mubarak Al-Kabeer Hospital, Jabriya - Department of Pulmonology; academic tertiary with the Faculty of Medicine, Kuwait University.
- Chest Diseases Hospital (Sabah Chest Hospital), Shuwaikh - dedicated chest-medicine specialty hospital; the principal national centre for chronic respiratory disease management.
- New Mowasat Hospital, Salmiya - private tertiary with pulmonology service for insured / expatriate patients.
- Royale Hayat Hospital, Hawally - private tertiary multi-specialty with pulmonology consultant roster.
The Chest Diseases Hospital (Sabah Chest Hospital) is the principal national chronic-respiratory disease referral centre and the most likely Brinsupri dispensing site for MOH-funded cases. High-resolution CT thorax for bronchiectasis confirmation is available at all the named tertiary centres.
Local pricing reference for Brinsupri in Kuwait
US WAC reference for Brinsupri (brensocatib, 10 mg and 25 mg oral tablets) is in the order of USD 7,000 to USD 9,000 per 30-day supply at the FDA-labelled 25 mg once-daily regimen. Source: FDA Drugs@FDA database.
No public KWD reference price for brensocatib has been observed on MOH or hospital published lists as of 2026-05-31. KWD reference at approximately 1 KWD = USD 3.25: the per-month indicative KWD reference is approximately KWD 2,200 to KWD 2,800.
Price snapshot date: 2026-05-31. Concomitant therapies (inhaled antibiotics, mucolytics, airway-clearance equipment) are locally sourced and are not part of the import file.
Country-specific access barriers for Brinsupri in Kuwait
The principal access barrier for brensocatib in Kuwait is the relative novelty of the indication and the molecule. Non-cystic-fibrosis bronchiectasis as a distinct phenotype with dedicated targeted-therapy options is a recent clinical category; many Kuwaiti pulmonologists have not yet prescribed brensocatib. The KDFC file therefore typically anchors on the FDA approval bulletin and the ASPEN trial publication (the pivotal trial supporting brensocatib's approval).
Public-sector funding posture: Kuwait MOH covers chronic respiratory care for nationals through MOH hospitals including the Chest Diseases Hospital; targeted oral therapies like brensocatib enter the MOH Specialty Pharmacy budget on case-by-case approval. For expatriate residents (approximately 70%), private insurance coverage of brensocatib is policy-specific; group-corporate policies covering chronic-respiratory therapy with annual caps are the typical mechanism.
The periodontal-disease pharmacovigilance signal in the FDA brensocatib label (the drug suppresses neutrophil serine proteases that also have a role in periodontal health) is referenced in the import file. Baseline dental assessment and dental follow-up are part of the monitoring axis; the dispensing pharmacy at Chest Diseases Hospital and Al-Sabah Hospital includes the dental-referral pathway in the file.
Ambient-storage oral tablets simplify customs handling. Each KDFC permit covers a defined supply window; chronic-therapy patients re-apply per cycle. The recurring permit administration is the operational discipline; the per-month drug cost is modest relative to most named-patient imports.
Recent local regulatory news touching Brinsupri or its drug class in Kuwait
No MOH KDFC bulletin specifically naming brensocatib or the DPP1 / cathepsin-C inhibitor class has been observed in the last twelve months on the MOH Kuwait news page as of 2026-05-31. Adjacent context:
- FDA approval of brensocatib in 2025 is the recent regulatory event for the drug; ongoing post-marketing safety surveillance continues. Source: FDA Drugs@FDA database.
- The European Respiratory Society and the American Thoracic Society have updated bronchiectasis management guidance; regional respiratory-medicine professional societies typically follow with several months lag. ARCH-74 to track. Source: European Respiratory Society.
What your physician needs to provide
For a Kuwaiti-licensed specialist prescribing Brinsupri through the DRD-MOH pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's confirmed diagnosis for non-cystic-fibrosis bronchiectasis in adults to reduce the frequency of pulmonary exacerbations, severity assessment (scoring instrument, biomarker, imaging, or biopsy as appropriate for the indication), prior therapy history including first-line options tried, and a clinical rationale for why Brinsupri is the appropriate next step given a first-in-class reversible inhibitor of dipeptidyl peptidase 1 (DPP1, also known as cathepsin C), the enzyme that activates neutrophil serine proteases (neutrophil elastase, proteinase 3, cathepsin G); inhibition reduces airway neutrophilic inflammation that drives bronchiectasis exacerbations.
The letter also specifies the exact dosing plan per the FDA-approved label: starting dose, maintenance dose, route of administration, schedule, and intended duration of therapy. Monitoring plan should reference any baseline laboratory or imaging requirements specific to Brinsupri (full blood count, liver function, infection screen, ophthalmology assessment, or pregnancy testing where the FDA label requires it), planned follow-up intervals, and dose-modification criteria for the most common adverse events.
The treating physician's Kuwaiti license number, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. For cold-chain or specialty-handling products, the dispensing pharmacy's documented storage protocol and continuous-temperature-monitoring log are part of the chain-of-custody record we share with the importer.
Common questions about Brinsupri in Kuwait
Will MOH public coverage, GIG Kuwait, and Warba Insurance cover this? Each insurer assesses named-patient imports case by case. Some reimburse fully when Brinsupri is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.
Is the FDA-approved indication recognised by DRD-MOH? The DRD-MOH named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; DRD-MOH review focuses on the clinical justification rather than re-litigating the FDA decision.
My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine? Any Kuwaiti-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. Kuwait Medical Association and the Kuwait MOH licensing directorate verifies the active license; the DRD-MOH application records both the prescribing physician and the dispensing facility.
Can I receive Brinsupri at home? The dispensing facility must be Kuwaiti-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.
What about competitors or alternative therapies in the same class? Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.
Where Reserve Meds fits in Brinsupri cases
Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace DRD-MOH, and we do not replace your dispensing pharmacy. For Brinsupri specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Kuwait, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.
Operationally, a typical Brinsupri case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the DRD-MOH application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.
Brinsupri is dosed orally once daily; periodontal-health monitoring (gingival changes have been observed in clinical trials) and pulmonary-function follow-up are part of the care plan.
Next step
If your Kuwaiti physician has prescribed Brinsupri and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.